B
BridGene Biosciences
Biotech & Life Sciences · San Jose, United States · Founded 2018
Biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules MoreLess
BridGene Biosciences, Inc. is a biotechnology company based in Sunnyvale, CA, specializing in the discovery of novel drug targets and the development of new therapeutics for unmet medical needs. The company employs a proprietary chemoproteomic platform called IMTAC™ to develop covalent drugs for high-value, hard-to-drug targets, including those involving protein-protein interactions or shallow binding pockets. This platform integrates advanced technologies such as covalent chemistry, chemical proteomics, and quantitative mass spectrometry. BridGene also utilizes a Target-Oriented Discovery approach, leveraging its industry-leading expertise to identify and develop new drug candidates.
The company primarily serves pharmaceutical and biotechnology firms looking for innovative solutions to complex medical challenges. Operating in the highly competitive biotechnology market, BridGene's business model focuses on research and development, partnering with other companies for drug development, and potentially licensing its proprietary technologies. Revenue is generated through these partnerships, licensing agreements, and milestone payments.
Keywords: chemoproteomics, covalent drugs, drug discovery, protein interactions, mass spectrometry, biotechnology, therapeutics, unmet medical needs, pharmaceutical partnerships, proprietary platform.
Company overview
BridGene Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Jose, United States
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 83.5
Valuation & funding
BridGene Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2025 | $28M | $193M | ShenZhen GTJA Investment Group · Proxima Ventures · Lapam Capital · Grains Valley Venture Capital | ↗ |
| SERIES BOther financing | Jul 2022 | $39M | $154M | Junson Capital · Dyee Capital · Lapam Capital | ↗ |
| FundingOther financing | May 2021 | $12M | — | Takeda · Kaitai Capital | — |
| SPINOUTOther financing | May 2018 | $0 | — | University of Southern California | — |
Growth signals
BridGene Biosciences website traffic
Latest recorded traffic for BridGene Biosciences is 2.5K monthly website visits, up 19% over the last three months. BridGene Biosciences's team grew 47.6% over the past year.
Comparisons
BridGene Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
BridGene Biosciences's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on BridGene Biosciences's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where BridGene Biosciences has talent and traffic
team presence
In the news
Latest news about BridGene Biosciences
Recent press, funding announcements, and product moves mentioning BridGene Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about BridGene Biosciences
An AI-synthesized read of the highest-engagement posts about BridGene Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BridGene Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.